RPTX Options (RPTX20260417C2.5) Price & Quote

Symbols

--(--)

Expected P&L on Expiry

Key Stats

0.00DAY`S RANGE0.00

Open

0.00

Prev.Close

0.00

Turnover

Volume

Premium

Extrinsic Value

Open Interest

Intrinsic Value

Pricing Model

Delta

Gamma

Theta

Vega

Rho

Theor Price

About RPTX20260417C2.5

Underlying

Repare Therapeutics Inc.

Industry

Introduction

Repare Therapeutics Inc. was incorporated on September 6, 2016 under the Canadian Business Corporations Act. The company is a leading precision oncology company with proprietary synthetic-killing methods that can be used to discover and develop novel therapies. Synthetic lethality, or SL, represents a clinically proven approach to drug development. The company uses its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies for genomic instability, including DNA damage repair. SL occurs when the deletion of either of the two genes is tolerated in the cell, but the simultaneous deletion of both genes leads to cell death. SL occurs when a deficiency of either of two genes in a cell is tolerated, but a simultaneous deficiency of both genes can lead to cell death. The company is using its SNIPRx platform to develop its pipeline of SL product candidates, including its product candidate RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.